Diagnostics Solutions Strategic Priorities
Integrated oncology decision support
AI-enabled digital solutions for informed, efficient patient management
Roche
NAVIFYⓇ Digital Pathology
PD-L1 Algorithm
Interpretation
of biomarker
NAVIFYⓇ
Mutation Profiler
Therapy options
& clinical trials
NAVIFYⓇ
Tumor Board
Radiology, pathology
& clinical data together
Flatiron and
Foundation Medicine
Access to clinico-
genomics database
Quick, accurate
answers for
patients
Clinically significant variants and combinations - Tier I & II (2)
variant
EGFR p.L858R
VAF 39% RD 7,478
Therapies approved/guidelines-recommended in: Non-small cell lung carci
° afatinib
bevacizumab + erlotinib
⚫dacomitinib
erlotinib + ramucirumab
gefitinib
⚫osimertinib
variant
TP53 p.P72R
VAF 100%
RD 2711
no approved therapies
53
SURGINGATIMENTS
Confident decisions
& standardized care
67View entire presentation